Profit Margin (Quarterly) Chart

Historical Profit Margin (Quarterly) Data

View and export this data back to 1995. Start Trial.
Date Value
June 30, 2026 17.01%
March 31, 2026 16.39%
December 31, 2025 12.84%
September 30, 2025 13.32%
June 30, 2025 -5.58%
March 31, 2025 7.14%
December 31, 2024 11.75%
September 30, 2024 11.61%
June 30, 2024 13.26%
March 31, 2024 16.17%
December 31, 2023 10.07%
September 30, 2023 18.41%
June 30, 2023 25.05%
March 31, 2023 23.87%
December 31, 2022 18.41%
September 30, 2022 33.27%
June 30, 2022 21.47%
March 31, 2022 20.70%
December 31, 2021 26.75%
September 30, 2021 26.75%
June 30, 2021 5.65%
March 31, 2021 18.63%
December 31, 2020 20.56%
September 30, 2020 16.34%
June 30, 2020 33.41%
Date Value
March 31, 2020 18.70%
December 31, 2019 64.59%
September 30, 2019 7.85%
June 30, 2019 8.57%
March 31, 2019 24.14%
December 31, 2018 10.05%
September 30, 2018 10.67%
June 30, 2018 22.67%
March 31, 2018 12.03%
December 31, 2017 31.66%
September 30, 2017 10.96%
June 30, 2017 17.62%
March 31, 2017 15.38%
December 31, 2016 5.66%
September 30, 2016 14.42%
June 30, 2016 19.02%
March 31, 2016 23.13%
December 31, 2015 21.38%
September 30, 2015 20.21%
June 30, 2015 22.38%
March 31, 2015 21.28%
December 31, 2014 24.07%
September 30, 2014 18.56%
June 30, 2014 28.99%
March 31, 2014 30.43%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Repligen Corp. 2.45%
BioLife Solutions, Inc. --
MindWalk Holdings Corp. -158.7%
Maravai Lifesciences Holdings, Inc. -42.05%
MaxCyte, Inc. -122.0%